Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study)
Purpose Candida spp. are frequently recovered from endotracheal secretions in critically ill patients suspected of having ventilator-associated pneumonia. Observational studies reported an association with worse clinical outcomes but the effect of antifungal therapy in these patients remains unclear. We designed this pilot study to assess the feasibility of a larger trial and to evaluate inflammatory profiles and clinical outcomes in these patients. Methods We conducted a double-blind, placebo-controlled, multicenter pilot randomized trial of antifungal therapy in critically ill patients with a clinical suspicion of ventilator-associated pneumonia with positive airway secretion specimens for Candida spp. We also included an observational group without Candida spp. in their airway secretions. We measured recruitment rate, inflammatory and innate immune function profiles over time, and clinical outcomes. Results We recruited 60 patients into the randomized trial and 29 patients into the observational study. Markers of inflammation and all clinical outcomes were comparable between placebo and antifungal treatment group at baseline and over time. At baseline, plasma TNF-α levels were higher in patients with VAP and Candida compared to the observational group (mean ± SD) (21.8 ± 23.1 versus 12.4 ± 9.3 pg/ml, p = 0.02) and these patients had lower innate immune function as evidenced by reduced whole blood ex vivo LPS-induced TNF-α production capacity (854.8 ± 855.2 versus 1,559.4 ± 1,290.6 pg/ml, p = 0.01). Conclusions This study does not provide evidence to support a larger trial examining the efficacy of empiric antifungal treatment in patients with a clinical suspicion of ventilator-associated pneumonia and Candida in the endotracheal secretions. The presence of Candida in the lung may be associated with persistent inflammation and immunosuppression..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Intensive care medicine - 40(2014), 9 vom: 01. Juli, Seite 1313-1322 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Albert, Martin [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Antifungal therapy |
|---|
| Anmerkungen: |
© Springer-Verlag Berlin Heidelberg and ESICM 2014 |
|---|
| doi: |
10.1007/s00134-014-3352-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR001225596 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR001225596 | ||
| 003 | DE-627 | ||
| 005 | 20230519082246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201001s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00134-014-3352-2 |2 doi | |
| 035 | |a (DE-627)SPR001225596 | ||
| 035 | |a (SPR)s00134-014-3352-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Albert, Martin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study) |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer-Verlag Berlin Heidelberg and ESICM 2014 | ||
| 520 | |a Purpose Candida spp. are frequently recovered from endotracheal secretions in critically ill patients suspected of having ventilator-associated pneumonia. Observational studies reported an association with worse clinical outcomes but the effect of antifungal therapy in these patients remains unclear. We designed this pilot study to assess the feasibility of a larger trial and to evaluate inflammatory profiles and clinical outcomes in these patients. Methods We conducted a double-blind, placebo-controlled, multicenter pilot randomized trial of antifungal therapy in critically ill patients with a clinical suspicion of ventilator-associated pneumonia with positive airway secretion specimens for Candida spp. We also included an observational group without Candida spp. in their airway secretions. We measured recruitment rate, inflammatory and innate immune function profiles over time, and clinical outcomes. Results We recruited 60 patients into the randomized trial and 29 patients into the observational study. Markers of inflammation and all clinical outcomes were comparable between placebo and antifungal treatment group at baseline and over time. At baseline, plasma TNF-α levels were higher in patients with VAP and Candida compared to the observational group (mean ± SD) (21.8 ± 23.1 versus 12.4 ± 9.3 pg/ml, p = 0.02) and these patients had lower innate immune function as evidenced by reduced whole blood ex vivo LPS-induced TNF-α production capacity (854.8 ± 855.2 versus 1,559.4 ± 1,290.6 pg/ml, p = 0.01). Conclusions This study does not provide evidence to support a larger trial examining the efficacy of empiric antifungal treatment in patients with a clinical suspicion of ventilator-associated pneumonia and Candida in the endotracheal secretions. The presence of Candida in the lung may be associated with persistent inflammation and immunosuppression. | ||
| 650 | 4 | |a Nosocomial infection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Intensive care |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a infection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antifungal therapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Williamson, David |4 aut | |
| 700 | 1 | |a Muscedere, John |4 aut | |
| 700 | 1 | |a Lauzier, Francois |4 aut | |
| 700 | 1 | |a Rotstein, Coleman |4 aut | |
| 700 | 1 | |a Kanji, Salmaan |4 aut | |
| 700 | 1 | |a Jiang, Xuran |4 aut | |
| 700 | 1 | |a Hall, Mark |4 aut | |
| 700 | 1 | |a Heyland, Daren |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Intensive care medicine |d Berlin : Springer, 1975 |g 40(2014), 9 vom: 01. Juli, Seite 1313-1322 |w (DE-627)SPR001167375 |w (DE-600)1459201-0 |x 1432-1238 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2014 |g number:9 |g day:01 |g month:07 |g pages:1313-1322 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00134-014-3352-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2014 |e 9 |b 01 |c 07 |h 1313-1322 | ||